RxDoctor Payments Data

Christoph Mai, MD

Ophthalmology · Aiea, HINPI 1083728844

Payments from drug & device makers

$866in general payments, 2019–2025

Across 33 payments — averaging $26.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$262
  • Merz North America, Inc.$134
  • Galderma Laboratories, L.p.$129
  • Sun Pharmaceutical Industries Inc.$92
  • Alcon$45
  • Tarsus Pharmaceuticals, Inc.$38
  • plus $167 from 7 others

What the payments were for

  • Food & beverage$866100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$866 in reported general payments places this provider in the 30th percentile of 120 ophthalmology providers in Hawaii.

See all ophthalmology providers in Hawaii

Medicare billing

Part B allowed, 2024
$62,549
Medicare patients
161
Services billed
809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost63$48,118
RocklatanNetarsudil Mesylat/Latanoprost51$43,575
Brimonidine Tartrate57$19,316
RhopressaNetarsudil Mesylate16$18,468
VyzultaLatanoprostene Bunod23$15,314
CombiganBrimonidine Tartrate/Timolol25$13,924
Alphagan PBrimonidine Tartrate11$9,310
Latanoprost215$5,262
Timolol Maleate154$4,678
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$2,242
Dorzolamide Hcl11$400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$262$71,35299 claims
Bausch & Lomb Americas Inc.Vyzulta$16$15,31423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 120 ophthalmology providers in Hawaii.

Other ophthalmology in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →